Brain Health in Breast Cancer Survivors

Description

Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.

Conditions

Cognitive Impairment, Cognitive Function

Study Overview

Study Details

Study overview

Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.

Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy

Brain Health in Breast Cancer Survivors

Condition
Cognitive Impairment
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California at Los Angeles, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 35-65
  • * Fluent in English
  • * Adequate vision/hearing to complete testing
  • * History of major or mild neurocognitive disorder or dementia
  • * Diagnosis of major neurological condition (e.g., epilepsy, Parkinson's Disease, stroke)
  • * Diagnosis of a major psychiatric disorder (e.g., bipolar disorder, schizophrenia)
  • * Untreated/unstable unipolar depression or anxiety
  • * Prior history of cancer or chemotherapy (for controls, any history)
  • * History of a learning disorder
  • * History of head injury with loss of consciousness \>20 minutes
  • * History of salpingo-oophorectomy or hysterectomy
  • * A cardiac pacemaker
  • * Implanted electronic device
  • * Claustrophobia
  • * Currently pregnant
  • * Orbital metal implant or other metallic foreign bodies

Ages Eligible for Study

35 Years to 65 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Jonsson Comprehensive Cancer Center,

Kathleen Van Dyk, PhD, PRINCIPAL_INVESTIGATOR, University of California at Los Angeles

Study Record Dates

2026-03-15